Rituximab rescue therapy for refractory early acute rejection after liver transplantation

European Journal of Inflammation

Volumn 8, Issue 2, 2010, Pages 125-129

  Vogel, Thomas ^a   Wolters, H H ^a   Holzen J ^a   Schmidt, H H ^b   August, C ^b   Dahrenmoller C ^a   Senninger, N ^a   Brockmann, J G ^c  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Liver transplantation; Resistant rejection; Rituximab

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ABSENCE OF SIDE EFFECTS; ACUTE GRAFT REJECTION; ADULT; ARTICLE; CASE REPORT; CONVALESCENCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; HUMAN; LIVER BIOPSY; LIVER FUNCTION; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATION; RARE DISEASE; TREATMENT OUTCOME;

EID: 80053544972     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727X1000800210     Document Type: Article

References (11)

1. Krukemeyer MG, Moeller J, Morawietz L, Rudolph B, Neumann U, Theruvath T, Neuhaus P, Krenn V. Description of B lymphocytes and plasma cells, complement, and chemokines/receptors in acute liver allograft rejection. Transplantation 2000; 78:65-70.
2. Alausa M, Almagro U, Siddiqi N, Zuiderweg R, Medipalli R, Hariharan S. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab. Clin Transplant 2005; 19:137-40. (Pubitemid 40227865)
3. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4:996-1001. (Pubitemid 38745599)
4. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006; 6:859-66. (Pubitemid 44356635)
5. Adams DH, Neuberger JM. Patterns of graft rejection following liver transplantation. J Hepatol 1990; 10:113-9. (Pubitemid 20006997)
6. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80:1233-43. (Pubitemid 41746802)
7. Sarwal M, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Masek M, Salvatierra O Jr. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349:125-38. (Pubitemid 36818782)
8. Aranda JM Jr, Scornik JC, Normann SJ, Lottenberg R, Schofield RS, Pauly DF, Miles M, Hill JA, Sleasman JW, Skoda-Smith S. Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation 2002; 73:907-10. (Pubitemid 34252353)
9. Agarwal A, Vieira CA, Book BK, Sidner RA, Fineberg NS, Pescovitz MD. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am J Transplant 2004; 4:1357-60. (Pubitemid 39013585)
10. Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with posttransplant lymphoproliferative disorder (PTLD). Am J Transplant 2005; 5:2901-6. (Pubitemid 43923950)
11. Cartron G, Blasco H, Paintaud G, Watier H, Le GC. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 2007; 62:43-52. (Pubitemid 46330791)